Shah Gaurav sold $8K of RCKT

Rocket Pharmaceuticals (RCKT) announced FDA agreement to include 3 patients in its Phase 2 trial for Danon disease gene therapy RP-A501, with 9 more to be enrolled. The modified protocol includes dose adjustments and enhanced safety monitoring. The FDA confirmed 12-month co-primary endpoints for efficacy. The trial aims to complete dosing by mid-2027, with primary assessment 12 months post-treatment. Safety and efficacy data remain key uncertainties.

Major U.S. mortgage lenders adjusted their 30-year fixed rates following the Federal Reserve's rate hike. Rocket Mortgage and Bank of America increased rates, while U.S. Bank lowered its. Freddie Mac reported a national average rate of 6.76%, with refinance applications dropping 9% week-over-week. Home-equity products saw increased interest, and the NAHB/Wells Fargo Housing Market Index fell to 32 in September.

Analysts upgraded several companies: Needham upgraded Similarweb (SMWB) to Buy with a $11 target, Wolfe Research upgraded Paychex (PAYX) to Peer Perform, Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target, UBS upgraded Union Pacific (UNP) to Buy with a $339 target, and Barclays upgraded Alvotech (ALVO) to Overweight with a $8 target.

Rocket Pharmaceuticals (RCKT) received an FDA alignment on a pivotal study for its genetic disease therapy, leading to a 'Buy' upgrade from Needham with a $9 price target, implying 150% upside. The FDA confirmed continued enrollment in the Phase 2 study of RP-A501 for Danon Disease, with dosing expected to complete by mid-2027. The stock was up 7.6% on the news.

Needham upgraded Rocket Pharmaceuticals (RCKT) from Hold to Buy, setting a $9.00 price target. The company's current price is $3.415, with a GF Score of 25/100. Insiders sold $432,273 worth of shares in the last three months. RCKT focuses on gene therapies for rare diseases and has no market-ready products.

Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 price target after FDA approved the trial design for RP-A501, a gene therapy for Danon Disease. The FDA's modifications include dosing and patient inclusion criteria. RCKT has no revenue, a $375M market cap, and a GF Score of 25, indicating financial stability but operational challenges. Insiders sold $1.0M in shares over the past year, while institutional guru ownership remains steady.